Clinical Trials on Blood Coagulation Tests in Netherlands

Total 3412 results

VarmX B.V.

Recruiting

Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant

Coagulation Disorder

Netherlands
VarmX B.V.

Completed

Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects

Coagulation Disorder

Netherlands
HagaZiekenhuis

Completed

Evaluation of Total Blood Volume Measurement During Dialysis on the Incidence of Intradialytic Hypotension

Hemodialysis Complication | Hypotension During Dialysis | Diagnostic Tests

Netherlands
CSL Behring

Completed

Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency

Congenital Coagulation Factor VII Deficiency

Netherlands, Norway
Radboud University Medical Center
Enzyre B.V.

Recruiting

Version Testing of EnzySystem Version A for Hemophilia A

Hemophilia A

Netherlands
Radboud University Medical Center

Active, not recruiting

He-move-philia, Lifestyle Intervention for Patients With Hemophilia

Hemophilia

Netherlands
Academisch Medisch Centrum - Universiteit van Amsterdam...

Recruiting

The ENDOCARDITIS AUMC Data Collection (ENDO_AUMC)

Coagulation Disorder | Endocarditis | Valve Disease, Heart

Netherlands
Marcella Muller
Università degli Studi dell'Insubria; Juntendo University; University of Chieti; Ospedale S. Antonio and other collaborators

Unknown

International Prospective Registry of Disseminated Intravascular Coagulation

Disseminated Intravascular Coagulation

Netherlands
Isala
CSL Behring

Completed

Haemocomplettan® P During Elective Complex Cardiac Surgery

Fibrinogen Deficiency in Complex Cardiac Surgery

Netherlands
Novo Nordisk A/S

Enrolling by invitation

Adverse Event Data Collection From External Registries on Nonacog Beta Pegol

Haemophilia B

Netherlands, United Kingdom
rEVO Biologics

Completed

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B (rhFVIIa)

Hemophilia

Netherlands, United States
Bayer

Completed

Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery (NO PEACKS)

Hemophilia A

Germany, Spain, Austria, Italy, Slovenia, Greece, Netherlands
CSL Behring

Active, not recruiting

Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B

Hemophilia B

Netherlands, Germany
Erasmus Medical Center
Shire; CSL Behring; Stichting Haemophilia (Dutch Haemophilia Foundation)

Unknown

Von Willebrand Disease in the Netherlands (WiN-Pro)

Von Willebrand Disease

Netherlands
Bayer

Completed

International PMS Study - KOGENATE Bayer

Hemophilia A

Switzerland, France, Spain, Sweden, Austria, Italy, Belgium, Denmark, Greece, Netherlands
Prothya Biosolutions

Completed

Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)

Hemophilia B

Netherlands
CSL Behring

Completed

Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B

Hemophilia B

Germany, Denmark, Netherlands
Radboud University Medical Center

Active, not recruiting

Assessment of Paravalvular Leak After TAVI by Hemodynamic Measurements and Cardiac MRI (APPOSE)

Aortic Valve Stenosis | Aortic Valve Insufficiency | Transcatheter Aortic Valve Replacement | Hemodynamic Monitoring | Acquired Von Willebrand Disease | Heyde's Syndrome

Netherlands
UMC Utrecht

Unknown

Cardiovascular Disease (CVD) in Haemophilia

Cardiovascular Disease | Haemophilia

Netherlands, United Kingdom
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation

Coagulation Disorder

United States, Spain, Belgium, France, Netherlands
Erasmus Medical Center
CSL Behring; Foundation Haemophilia

Completed

National Study of Moderate and Severe Von Willebrand Disease in the Netherlands (WiN)

Von Willebrand Disease

Netherlands
Pfizer

Completed

Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting

Hemophilia A

Spain, France, Turkey, Netherlands, Germany, Italy, Ukraine
Academisch Medisch Centrum - Universiteit van Amsterdam...

Unknown

The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B (DYNAMO)

Hemophilia

Netherlands, Austria, Australia, Belgium, Canada, Finland, Germany, Italy, Spain, United Kingdom
Bayer
Ultragenix pharmaceutical

Active, not recruiting

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle".

Hemophilia A

Netherlands, United States, Germany, United Kingdom, France, Bulgaria
Weill Medical College of Cornell University
Bayer; University Hospital, Bonn

Completed

Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study

Hemophilia A | Hemophilia B

United States, Israel, Australia, Italy, Sweden, Germany, Japan, Netherlands, Taiwan
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

Hemophilia A

Italy, United States, Netherlands, United Kingdom, Germany, New Zealand, Belgium, France
Kathelijn Fischer
Radboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaborators

Recruiting

Pharmacokinetic-guided Dosing of Emicizumab (DosEmi)

Adolescent | Child | Hemophilia A With Inhibitor | Adult | Hemophilia A Without Inhibitor | Hemophilia A, Severe

Netherlands
Vall d'Hebron Institute of Oncology
European Organisation for Research and Treatment of Cancer - EORTC

Terminated

Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

Chemotherapy | ColoRectal Cancer | MSI | Resistance, APC

Belgium, Netherlands, Spain, Italy
The University of Texas Health Science Center,...
Baxter Healthcare Corporation; Rho, Inc.

Completed

Hemophilia Inhibitor Previously Untreated Patient Study (HIPS)

Hemophilia A

United States, Austria, Italy, Netherlands, Sweden
Baxalta now part of Shire
Baxter Innovations GmbH

Terminated

Early Prophylaxis Immunologic Challenge (EPIC) Study (EPIC)

Hemophilia A

Poland, United States, Bulgaria, Serbia, Canada, Russian Federation, Germany, Netherlands, Lithuania, Czechia, Austria, Spain
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Terminated

BAX 802 in CHA With Inhibitors (CHAWI)

Hemophilia A

Netherlands, Spain, Italy, Turkey, Bulgaria, United States, Canada, Germany, Norway, Poland, Russian Federation, South Africa
Baxalta now part of Shire

Completed

BAX 826 Dose-Escalation Safety Study

Hemophilia A

Spain, Bulgaria, Germany, United Kingdom, Italy, Poland, Russian Federation, Netherlands, Hungary
Bayer

Active, not recruiting

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A (HEM-POWR)

Hemophilia A

Canada, Japan, Spain, United States, Germany, Sweden, Belgium, Brazil, Greece, Italy, Netherlands, Taiwan, Denmark, Kuwait, Saudi Arabia, United Arab Emirates, Norway, Colombia, Switzerland, Slovenia
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Acquired Hemophilia A

United States, Italy, United Kingdom, Germany, Austria, Netherlands, France
Baxalta now part of Shire

Completed

Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

Hemophilia A

United States, Spain, Netherlands, United Kingdom, Bulgaria, Lithuania, Russian Federation, Switzerland, Ukraine
Swedish Orphan Biovitrum
Syneos Health

Active, not recruiting

A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa (FREEDOM)

Hemophilia A, Severe

Germany, Spain, France, Czechia, Netherlands, Ireland, Austria, Croatia, Greece, Italy, Norway, Slovenia, Sweden, United Kingdom
Bayer

Completed

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis (TAURUS)

Hemophilia A, Congenital

Slovenia, Italy, Germany, France, United States, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan
Takeda
Baxalta Innovations GmbH, now part of Shire

Completed

rVWF IN PROPHYLAXIS

Von Willebrand Disease

United States, Spain, Italy, Turkey, Germany, Russian Federation, Netherlands, France, Canada
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B (Kids B-LONG)

Hemophilia B

United States, United Kingdom, South Africa, Netherlands, Ireland, Australia
Baxalta now part of Shire

Active, not recruiting

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Hemophilia A

Spain, Thailand, Hungary, Taiwan, Korea, Republic of, Czechia, Germany, Sweden, Italy, Croatia, United States, Bulgaria, Netherlands
Swedish Orphan Biovitrum

Active, not recruiting

A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health (A-MORE)

Hemophilia A

Spain, Germany, Czechia, Italy, Estonia, Finland, Greece, Netherlands, Saudi Arabia, Slovenia, Sweden, Switzerland, United Kingdom
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A (Kids ALONG)

Hemophilia A

United States, Poland, United Kingdom, Netherlands, South Africa, Hong Kong, Australia, Ireland
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

Hemophilia A

United States, Belgium, France, Norway, Netherlands, Austria, Hungary, Italy, Poland, Portugal, Romania, Russian Federation, Spain, Sweden
Academisch Medisch Centrum - Universiteit van Amsterdam...
ZonMw: The Netherlands Organisation for Health Research and Development

Completed

Transfusion of Fresh Frozen Plasma in Non-bleeding Intensive Care Unit (ICU) Patients (TOPIC)

Hemorrhage | Blood Coagulation Disorders

Netherlands
Hemab ApS

Recruiting

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

Glanzmann Thrombasthenia

United States, Belgium, France, Italy, Netherlands, United Kingdom
Octapharma

Completed

Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A

Severe Haemophilia A

France, Japan, United States, Canada, Croatia, Finland, Netherlands, North Macedonia, Slovenia
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Von Willebrand Disease (VWD)

United States, Italy, Spain, Netherlands, Turkey, France, Austria, Germany, Russian Federation
Novo Nordisk A/S

Completed

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A (pathfinder™7)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Germany, France, Denmark
Baxalta now part of Shire

Completed

BAX 855 Pediatric Study

Hemophilia A

United States, Spain, United Kingdom, Taiwan, Malaysia, Bulgaria, Hong Kong, Korea, Republic of, Netherlands, Turkey, Ukraine
CSL Behring

Completed

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

Congenital Hemophilia A

United States, Austria, Germany, Malaysia, Netherlands, Philippines, Ukraine, Romania, Spain, Australia, France, Georgia, Italy, Lebanon, Poland, Portugal, Switzerland, Thailand, Turkey

Clinical Trials on Blood Coagulation Tests in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations